Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Announces $65 Million Oversubscribed Offering
August 12, 2022 08:00 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 08, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in ChinaIND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in...
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
July 27, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022
June 22, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement...
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022
June 08, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer
June 01, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
- Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development FOSTER CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the...
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023 -TERN-601...
Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 04, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...